Literature DB >> 9568781

Long-term cancer patient survival in the United States.

P A Wingo1, L A Ries, S L Parker, C W Heath.   

Abstract

Although survival rates are useful for monitoring progress in the early detection and treatment of cancer and are of particular interest to patients with new diagnoses, there are limited population-based estimates of long-term survival rates. We used data collected by the Surveillance, Epidemiology, and End Results Program for cases diagnosed during 1974-1991 and followed through 1992 to estimate relative survival at 5, 10, and 15 years after diagnosis of cancer of the breast, prostate, colon and rectum, and lung. Relative survival after diagnosis of breast and prostate cancer continued to decline up through 15 years after diagnosis, whereas survival after diagnosis of lung and colon or rectal cancer remained approximately constant after 5 and 10 years, respectively. Age-specific patterns of survival varied by site, stage, and demographics. Among patients with localized breast and prostate cancer, women who were younger than age 45 at breast cancer diagnosis and men who were 75 years and older at prostate cancer diagnosis had the poorest relative survival. Relative survival among lung cancer patients decreased with age at diagnosis, regardless of stage or demographics, and age-specific patterns of relative survival for patients with cancer of the colon and rectum differed according to race. Among white patients diagnosed with cancers of the colon and rectum, relative survival did not vary by age at diagnosis; among black patients older than 45 at diagnosis, relative survival decreased with age. This study provides population-based estimates of long-term survival and confirms black/white, male/female, and stage- and age-specific differences for the major cancers.

Entities:  

Mesh:

Year:  1998        PMID: 9568781

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  25 in total

1.  Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.

Authors:  Nan Li; Yaguang Xi; Heather N Tinsley; Evrim Gurpinar; Bernard D Gary; Bing Zhu; Yonghe Li; Xi Chen; Adam B Keeton; Ashraf H Abadi; Mary P Moyer; William E Grizzle; Wen-Chi Chang; Margie L Clapper; Gary A Piazza
Journal:  Mol Cancer Ther       Date:  2013-06-26       Impact factor: 6.261

Review 2.  Age-related racial disparities in prostate cancer patients: A systematic review.

Authors:  Ting He; C Daniel Mullins
Journal:  Ethn Health       Date:  2016-10-05       Impact factor: 2.772

3.  History of cancer and mortality in community-dwelling older adults.

Authors:  Elizabeth Kvale; O James Ekundayo; Yan Zhang; Shamima Akhter; Inmaculada Aban; Thomas E Love; Christine Ritchie; Ali Ahmed
Journal:  Cancer Epidemiol       Date:  2010-08-13       Impact factor: 2.984

Review 4.  Chemotherapy-induced ovarian failure: manifestations and management.

Authors:  Julian R Molina; Debra L Barton; Charles L Loprinzi
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Temporal Trends in Geographic and Sociodemographic Disparities in Colorectal Cancer Among Medicare Patients, 1973-2010.

Authors:  Peter S Liang; Jonathan D Mayer; Jon Wakefield; Cynthia W Ko
Journal:  J Rural Health       Date:  2016-08-31       Impact factor: 4.333

6.  Fundamental causes of colorectal cancer mortality: the implications of informational diffusion.

Authors:  Andrew Wang; Sean A P Clouston; Marcie S Rubin; Cynthia G Colen; Bruce G Link
Journal:  Milbank Q       Date:  2012-09       Impact factor: 4.911

Review 7.  Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.

Authors:  Matthew J Matasar; Vijaya Sundararajan; Victor R Grann; Alfred I Neugut
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.

Authors:  Dawn L Hershman; Donald J McMahon; Katherine D Crew; Serge Cremers; Dinaz Irani; Gina Cucchiara; Lois Brafman; Elizabeth Shane
Journal:  J Clin Oncol       Date:  2008-08-18       Impact factor: 44.544

9.  Polycyclic aromatic hydrocarbon--DNA adducts in prostate and biochemical recurrence after prostatectomy.

Authors:  Benjamin A Rybicki; Christine Neslund-Dudas; Cathryn H Bock; Andrew Rundle; Adnan T Savera; James J Yang; Nora L Nock; Deliang Tang
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

10.  DICER1 and PRKRA in Colon Adenocarcinoma.

Authors:  S Chiosea; M Acquafondata; J Luo; Sf Kuan; Rr Seethala
Journal:  Biomark Insights       Date:  2008-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.